=== PAGE 5 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Santosh T. Varghese
VIVUS, Inc.
NDA 022580/ MA 414

OPDP requests that Vivus immediately cease violating the FD&C Act, as discussed above.
Please submit a written response to this letter on or before June 7, 2019, stating whether you
intend to comply with this request, listing all promotional materials (with the 2253 submission
date) for Vivus that contain violations such as those described above, and explaining your
plan for discontinuing use of such violative materials. If you believe that your products are
not in violation of the FD&C Act, include your reasoning and any supporting information for
our consideration.

Please direct your response to the undersigned at the **Food and Drug Administration,**
**Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-**
**B Ammendale Road, Beltsville, Maryland 20705-1266.** A courtesy copy can be sent by
facsimile to (301) 847-8444. To ensure timely delivery of your submissions, please use the
full address above and include a prominent directional notation (e.g. a sticker) to indicate that
the submission is intended for OPDP. Please refer to MA 414 in addition to the NDA number
in all future correspondence relating to this particular matter. All correspondence should
include a subject line that clearly identifies the submission as a Response to Untitled Letter.
OPDP reminds you that only written communications are considered official.

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for Vivus comply with each
applicable requirement of the FD&C Act and FDA implementing regulations.

Reference ID: 4437455
Page 5

Sincerely,

{See appended electronic signature page}

Meena Savani, PharmD, RAC
Regulatory Review Officer
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

{See appended electronic signature page}

Melinda McLawhorn, PharmD, MPH, BCPS,
RAC
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion
